Clinical Trial Update: Motivational Enhancement Therapy to Improve Adherence to Aromatase Inhibitors [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2/3 study evaluating motivational enhancement therapy to improve adherence to aromatase inhibitors in breast cancer has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Snippet

Sponsor: University of Calgary | Conditions: Breast Cancer, Medication Adherence | Phase 2, Phase 3 | Status: WITHDRAWN